NanoViricides, Inc. (NNVC) Financial Ratios
21 years of historical data (2005–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
2.86
↑+76% vs avg
5yr avg: 1.63
30Y Low0.9·High133.0
ROE
↓
-99.7%
↑-83% vs avg
5yr avg: -54.6%
30Y Low-359%·High-7%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NNVC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
NanoViricides, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $31M | $21M | $20M | $13M | $22M | $51M | $42M | $17M | $29M | $81M | $92M |
| Enterprise Value | $29M | $20M | $16M | $5M | $8M | $30M | $29M | $15M | $21M | $70M | $77M |
| P/E Ratio → | -2.25 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.86 | 2.82 | 1.78 | 0.90 | 0.94 | 1.69 | 1.93 | 1.63 | 1.62 | 3.99 | 4.00 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
NNVC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
NNVC Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -99.7% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -99.7% | -99.7% | -63.0% | -45.3% | -30.6% | -34.1% | -83.1% | -58.3% | -45.1% | -47.5% | -39.1% |
| ROA | -87.5% | -87.5% | -55.8% | -42.5% | -30.2% | -32.6% | -72.0% | -51.5% | -37.6% | -32.4% | -26.5% |
| ROIC | -114.0% | -114.0% | -95.5% | -84.8% | -65.4% | -70.2% | -69.6% | -69.7% | -70.8% | -86.4% | -88.6% |
| ROCE | -101.1% | -101.1% | -61.2% | -45.3% | -30.6% | -33.8% | -49.4% | -61.3% | -46.6% | -36.8% | -24.1% |
NNVC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.00 | 0.00 | 0.05 | — | — | 0.19 | 0.37 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.21 | -0.42 | -0.55 | -0.61 | -0.68 | -0.58 | -0.24 | -0.40 | -0.55 | -0.67 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -170.98 | -9534.61 | -1583.76 | -102.38 | -85.37 | — | -17.13 | -4.51 | -3.59 |
Net cash position: cash ($2M) exceeds total debt ($0)
NNVC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.28x means NanoViricides, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 15.81x to 1.28x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | 1.28 | 3.66 | 15.81 | 34.92 | 59.30 | 6.49 | 0.99 | 8.30 | 3.28 | 3.62 |
| Quick Ratio | 1.28 | 1.28 | 3.66 | 15.81 | 34.92 | 59.30 | 6.49 | 0.99 | 8.30 | 3.28 | 3.62 |
| Cash Ratio | 1.19 | 1.19 | 3.53 | 15.25 | 34.07 | 58.43 | 6.36 | 0.90 | 8.03 | 3.24 | 3.58 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
NNVC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
NanoViricides, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $15M | $12M | $12M | $12M | $11M | $6M | $4M | $3M | $3M | $3M |
Peer Comparison
Compare NNVC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NNVCYou | $31M | -2.3 | — | — | — | — | -99.7% | -114.0% | — |
 SIGA | $339M | 14.3 | 7.6 | 7.0 | 68.6% | 25.1% | 11.2% | 33.7% | 0.0 |
 COCP | $18M | -0.8 | — | — | — | — | -97.5% | -799.8% | — |
 GILD | $166B | 19.8 | 17.0 | 17.6 | 86.7% | 40.1% | 40.7% | 23.4% | 2.3 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 RGEN | $7B | 147.0 | 52.4 | 75.9 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
 NVAX | $2B | 3.6 | 2.6 | — | 93.7% | 50.1% | — | — | 0.4 |
 VXRT | $178M | 10.6 | 7.4 | 23.5 | — | 7.6% | 22.3% | 27.1% | 0.5 |
 IBRX | $8B | -12.5 | — | — | 100.0% | -2334.2% | — | — | — |
 BRKR | $7B | -291.5 | 18.4 | 153.7 | 45.9% | 6.9% | -0.4% | 4.4% | 4.5 |
 AVTR | $6B | -10.7 | 56.4 | 11.5 | 32.7% | -3.8% | -9.2% | -2.0% | 24.1 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 21 years · Updated daily
See NNVC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NNVC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NNVC vs SIGA
Side-by-side business, growth, and profitability comparison vs SIGA Technologies, Inc..
Start ComparisonNNVC — Frequently Asked Questions
Quick answers to the most common questions about buying NNVC stock.
What is NanoViricides, Inc.'s P/E ratio?
NanoViricides, Inc.'s current P/E ratio is -2.3x. This places it at the 50th percentile of its historical range.
What is NanoViricides, Inc.'s ROE?
NanoViricides, Inc.'s return on equity (ROE) is -99.7%. The historical average is -83.1%.
Is NNVC stock overvalued?
Based on historical data, NanoViricides, Inc. is trading at a P/E of -2.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.